July 14th, 2021 — Bayer announced this week that their first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA), finerenone (Kerendia), has received FDA approval for use in patients with chronic kidney disease (CKD) associated with type 2 diabetes¹. The approval comes following the positive results of the FIDELIO-DKD clinical trial, a Phase…
